Announcement PDF AMPLIA THERAPEUTICS LIMITED ACN 165 160 841 PROSPECTUS This Prospectus is being issued for an offer of New Shares to Eligible Shareholders under a Share Purchase Plan (SPP) at the SPP Offer Price to raise $2.5 million, with the ability to accept over-subscriptions of up to an additional $7.5 million worth of New Shares. This Prospectus also includes the SPP Shortfall Offer. The SPP and the SPP Shortfall Offer are conditional on Shareholder approval. The Closing Date of the SPP is 5.00pm on Friday, 22 August 2025. The SPP and the SPP Shortfall Offer are being lead managed, but not underwritten, by Bell Potter Securities Limited. IMPORTANT INFORMATION This Prospectus is important and should be read in its entirety. If after reading this Prospectus you have any questions about the securities being offered under this Prospectus or any other matter, then you should consult your stockbroker, accountant or other professional adviser. The Shares offered under this Prospectus should be considered as speculative. Not for release to US wire services or distribution in the United States amtl0001_2500183_057.docx IMPORTANT NOTICE Prospectus This Prospectus relates to the offer of new, fully paid ordinary shares (New Shares) by Amplia Therapeutics Limited ACN 165 160 841 (Amplia or Company) under the SPP and the SPP Shortfall Offer. The offer made under this Prospectus is only being made Eligible Shareholders (in relation to the SPP) or Institutional Investors selected by the Lead Manager and the Company (in relation to the SPP Shortfall Offer). It is not being made to the general public. The SPP is not underwritten. This Prospectus is dated Friday, 1 August 2025 (Prospectus Date) and a copy of the Prospectus was lodged with the Australian Securities and Investments Commission (ASIC) on that date. The expiry date of the Prospectus is 5.00pm (Melbourne time) on the date that is 13 months after the date of this Prospectus (Expiry Date). No securities will be issued on the basis of this Prospectus after the Expiry Date. Transaction-specific Prospectus This Prospectus is a ‘transaction-specific’ prospectus to which the special content rules under section 713 of the Corporations Act 2001 (Corporations Act) apply. This allows the issue of a concise prospectus in relation to an offer of securities in a class which has been continuously quoted by the Australian Securities Exchange (ASX) in the three months prior to the date of the prospectus. This Prospectus does not include all of the information that would be disclosed for an initial public offering of securities. An application for admission of the New Shares to quotation on the ASX has been made to ASX (on 23 July 2025). ASX maintains a database of publicly available information issued by the Company as a disclosing entity. This Prospectus should be read in conjunction with that information. None of ASIC, ASX or their respective officers, take any responsibility for the contents of this Prospectus or the merits of the securities to which this Prospectus relates. ASIC Instrument 2019/547 In certain circumstances, a listed company may undertake a share purchase plan in accordance with ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 (Instrument 2019/547). Instrument 2019/547 allows a share purchase plan to be conducted without the use of a prospectus for a maximum of $30,000 worth of securities to a participant in a 12 month period. The Company is unable to rely on Instrument 2019/547 for the SPP because the SPP exceeds the monetary limit under Instrument 2019/547 as it is for up to $100,000 worth of New Shares to Eligible Shareholders. Accordingly, the Company is undertaking the SPP under this Prospectus. SPP is conditional on Shareholder approval The SPP is conditional on Shareholder approval for the purposes of ASX Listing Rule 7.1. This is because Amplia utilised substantially all of its capacity under ASX Listing Rules 7.1 and 7.1A under the Placement and is not entitled to rely on ASX Listing Rule 7.2, Exception 5 because Eligible Shareholders are being offered up to $100,000 worth of New Shares under the SPP. The resolution to approve the SPP (and the SPP Shortfall Offer) will be considered at the AGM. If the SPP is not approved at the AGM it will not proceed. Exposure period and cooling off rights No exposure period applies to this Prospectus by operation of ASIC Corporations (Exposure Period) Instrument 2016/74. Cooling off rights do not apply to an investment in New Shares. You cannot withdraw your Application once it has been received. Obtaining a Prospectus and Application Form Applications for New Shares offered pursuant to this Prospectus can be submitted on an Application Form. Eligible Shareholders will be able to access a personalised Application Form at www.computersharecas.com.au/ATXSPP2025. The Application Form will be accompanied by a copy of the Prospectus, which will also be available from the ASX website (www.asx.com.au). Paper copies of this Prospectus and an Application Form can be obtained free of charge during the Offer Period by contacting the Company at info@ampliatx.com or the Company Secretary on andrew@ampliatx.com. Electronic prospectus This Prospectus is available electronically and accompanies the Application Form (which will be available at www.computersharecas.com.au/ATXSPP2025). Electronic versions of this Prospectus should be downloaded and read in its entirety. Applications for New Shares under the SPP may only be made on the Application Form by following the instructions in the Application Form. Investor warning The Offer contained in this Prospectus does not take into account the investment objectives, financial position and particular needs of individual investors. It is important that you read this Prospectus carefully and in full before deciding to apply for New Shares. In particular, you should consider the risk factors that could affect the performance of the Company in light of your personal circumstances and seek advice from your accountant, tax adviser, stockbroker, lawyer or other professional adviser before deciding to invest. Page |1 amtl0001_2500183_057.docx No representation other than in this Prospectus No person is authorised to give information or to make any representation in connection with this Prospectus, which is not contained in the Prospectus. Any information or representation not so contained may not be relied on as having been authorised by the Company in connection with this Prospectus. Except as required by law, and only to the extent so required, neither Amplia nor any other person warrants or guarantees the future performance of the Company or any return on any investment made pursuant to this Prospectus. Risk factors Potential investors should be aware that subscribing for the New Shares involves a number of risks. The key risk factors which investors should be aware of are set out in Section 7 of this Prospectus. These risks, together with other general risks applicable to all investments in listed and unlisted securities, which are not specifically referred to, may affect the value of the New Shares in the future. Eligible Shareholders and Offer jurisdictions The New Shares to be issued under the SPP will only be offered to Eligible Shareholders, being Shareholders as at 7.00pm (Melbourne time) on the Record Date with a registered address in Australia or New Zealand (or otherwise determined by the Company at its discretion). The distribution of this Prospectus in jurisdictions outside Australia and New Zealand may be restricted by law. Seek advice on and observe any restrictions. This Prospectus is not an offer in any place where, or to any person to whom, it would not be lawful to make the Offer. In particular, the New Shares have not been, and will not be, registered under US Securities Act and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the US Securities Act and applicable US state securities laws. You may only apply for New Shares in Australian dollars. You can contact the Company at info@ampliatx.com or the Company Secretary on andrew@ampliatx.com, if you are an Eligible Shareholder but are unable to pay for New Shares by BPAY. Financial information and forward looking statements Section 6 sets out the financial information referred to in this Prospectus and the basis of preparation of that information. Any discrepancies between totals and sums of components in tables contained in this Prospectus are due to rounding. This Prospectus contains forward looking statements which are identified by words such as “may”, “could”, “believes”, “estimates”, “expects”, “intends” and other similar words that involve risks and uncertainties. Any forward looking statements are subject to various risk factors that could cause the Company’s actual results to differ materially from the results expressed or anticipated in these statements. Forward looking statements should be read in conjunction with the risk factors set out in Section 7 and the other information in this Prospectus. Taxation implications The Directors do not consider it appropriate to give Shareholders advice regarding the taxation consequences of applying for New Shares under this Prospectus (and do not accept any responsibility or liability for any such consequences). Shareholders should consult their tax adviser as required. Defined words and expressions Some words and expressions used in this Prospectus have defined meanings. These words and expressions are defined throughout the Prospectus and in the Glossary in Section 10. A reference to $ or cents in this Prospectus is a reference to Australian currency (unless otherwise stated). A reference to time in this Prospectus is a reference to Melbourne, Australia time. Photographs and diagrams Any photographs used in this Prospectus without descriptions are only for illustration. Any diagrams used in this Prospectus may not be drawn to scale. Privacy If you apply for New Shares, you will provide personal information to the Company and the Share Registry. The Company and the Share Registry collect, hold and use your personal information in order to assess your Application, service your needs as a holder of the Shares, provide facilities and services that you request and carry out appropriate administration. Company and tax laws require some of the information to be collected. If you do not provide the information requested, your Application may not be able to be processed efficiently, or at all. Each of the Company and the Share Registry may disclose your personal information for purposes related to your shareholding to each other and to their respective agents and services providers including those listed below or as otherwise authorised under the Privacy Act 1988 (Cth) (Privacy Act): • in the case of the Company, to the Share Registry for ongoing administration of the Share (and option) registers; and • in the case of the Company and the Share Registry, to printers and mailing houses for the purposes of preparation and distribution of security holder information and for handling of mail. Under the Privacy Act, you may request access to your personal information held by (or on behalf of) the Company or the Share Registry. You can contact the Share Registry’s Privacy Officer at privacy@computershare.com.au or see our Privacy Policy at www.computershare.com/au/privacy-policies. Page |2 amtl0001_2500183_057.docx CONTENTS Section Page Important Notice 1 Contents 3 Key Dates 4 Key Details of the SPP and Capital Raising 5 1. Corporate Directory 8 2. Chairman’s Letter 9 3. Overview of the SPP and SPP Shortfall Offer 11 4. Applying under the SPP and SPP Shortfall Offer 16 5. Purpose and Effect of the Offer 23 6. Financial Information 25 7. Risk Factors 28 8. Rights and Liabilities Attaching to Shares 32 9. Additional Information 35 10. Glossary 41 Page |3 amtl0001_2500183_057.docx KEY DATES The key dates in respect of the SPP are as follows. Event Date Record Date Tuesday, 22 July 2025 (7.00pm) Record Date of the SPP Opening Date Prospectus lodged with ASIC and ASX Prospectus made available to Eligible Shareholders Friday, 1 August 2025 SPP offer opens SPP pricing period commences Monday, 18 August 2025 Closing Date SPP closes (5.00pm time) Friday, 22 August 2025 Last day of SPP pricing period SPP Results Date Announcement of results of SPP and SPP Offer Price AGM Date Company holds AGM Settlement Date Settlement of the SPP* Allotment Date Issue of Shares under the SPP* Commencement of trading of New Shares issued under the SPP* Issue of New Shares under the Director Placement and Conditional Placement* Tuesday, 26 August 2025 Wednesday, 27 August 2025 Thursday, 28 August 2025 Friday, 29 August 2025 Monday, 1 September 2025 * Assumes Shareholders approve the SPP, Director Placement and Conditional Placement at the AGM. Amplia reserves the right to vary these times and dates, by agreement with the Lead Manager. All times are Melbourne times. Page |4 amtl0001_2500183_057.docx KEY DETAILS OF THE SPP AND CAPITAL RAISING Terms of the SPP and SPP Shortfall Offer SPP Offer Price The SPP Offer Price is the lower of: • the Placement Offer Price (being $0.23); and • the price representing a 5% discount to the volume weighted average price of Shares traded during the five trading days up to the Closing Date, rounded to the nearest half cent. Amount to be raised under the SPP The SPP is seeking to raise up to $2.5 million, however the Company reserves the right to accept over-subscriptions of up to an additional $7.5 million worth of New Shares under the SPP and SPP Shortfall Offer (for a total of $10.0 million worth of New Shares). Number of New Shares to be issued under the SPP Approximately 10,869,566 New Shares will be issued under the SPP, assuming the SPP is subscribed to $2.5 million and the SPP Offer Price is $0.23. Capital structure of the Company Shares on issue on the date of announcement of the Capital Raising 389,672,669 Shares Shares issued under the Unconditional Placement 96,804,354 Shares Proceeds raised via the Unconditional Placement (before costs) ~$22.3 million Shares on issue as at the Prospectus Date 486,477,023 Shares Shares to be issued under the SPP 10,869,566 Shares Proceeds to be raised via the SPP (before costs) $2.5 million Shares to be issued under the Conditional Placement 10,869,566 Shares Proceeds to be raised via the Conditional Placement (before costs) $2.5 million Shares to be issued under the Director Placement (before costs) 1,021,740 Shares Proceeds to be raised via the Director Placement (before costs) $0.2 million Shares to be issued under the Capital Raising 119,565,226 Shares Page |5 amtl0001_2500183_057.docx Total proceeds of the Capital Raising (before costs) $27.5 million Shares on issue on completion of the Capital Raising 509,237,895 Shares Market capitalisation at the Placement Offer Price (of $0.23) $117.1 million Options on issue on completion of the Capital Raising (assuming completion of the grants to Directors as contemplated by the Notice of AGM) 90,299,589 ATXOA Listed Options 19,231,000 unquoted options expiring from September 2025 to December 2028 with exercise prices from $0.132 to $0.2533 818,006 unquoted options to be issued to the Non-Executive Directors (subject to Shareholder approval) 447,000 Zero Exercise Priced Options to be issued to the Managing Director (subject to Shareholder approval) Capital structure of the Company if the SPP is subscribed to at least $10.0 million and the Company accepts the over-subscriptions up to the SPP Cap Maximum proceeds of the SPP assuming Applications of at least $10.0 million under the SPP and SPP Shortfall Offer are received and accepted in full (up to the SPP Cap) $10.0 million Shares to be issued under the SPP assuming $10.0 million raised (at $0.23 per New Share) 43,478,261 Shares Total proceeds of the Capital Raising in these circumstances $35.0 million Shares on issue on completion of the Capital Raising in these circumstances 541,846,590 Shares Market capitalisation at the Placement Offer Price (of $0.23) in these circumstances $124.6 million Notes: Unless otherwise stated, this Prospectus assumes $2.5 million worth of New Shares are issued under the SPP and SPP Shortfall Offer at an SPP Offer Price of $0.23 and Shareholders approve the SPP, Director Placement and Conditional Placement (and grant of options to Directors) at the AGM. Final numbers will vary slightly as a result of rounding. Provision of documents Eligible Shareholders who have elected to receive documents electronically from the Company will receive online access to the Prospectus and the Application Form (which accompanies the Prospectus) by email. Eligible Shareholders who have not elected to receive electronic communications will be posted a letter detailing how to access the Prospectus and Application Form at www.computersharecas.com.au/ATXSPP2025. Page |6 amtl0001_2500183_057.docx Information availability Eligible Shareholders can also obtain a copy of this Prospectus from the Company’s website, the ASX website (www.asx.com.au). The Prospectus will accompany the Application Form, which is made available to Eligible Shareholders at www.computersharecas.com.au/ATXSPP2025. Contact details are provided in the Corporate Directory. Shareholders who access the electronic version of this Prospectus should ensure that they download and read the entire Prospectus. The Application Form attached to the Prospectus must be used within Australia and New Zealand only. Enquiries For further information please contact the Company at info@ampliatx.com or the Company Secretary on andrew@ampliatx.com. Alternatively, contact your stockbroker, solicitor, accountant or other professional adviser. Page |7 amtl0001_2500183_057.docx 1 CORPORATE DIRECTORY Amplia Therapeutics Limited (ASX Code: ATX) Directors Registered Office Dr Warwick Tong (Non-Executive Chair) Level 5, 90 William Street Melbourne VIC 3000 Dr Christopher Burns (Managing Director, CEO) Dr Robert Peach (Non-Executive Director) Ms Jane Bell (Non-Executive Director) Email: info@ampliatx.com Website: www.ampliatx.com Company Secretary Lead Manager Mr Andrew Cooke andrew@ampliatx.com Bell Potter Securities Limited Level 29, 101 Collins Street Melbourne VIC 3000 Chief Financial Officer Mr Tim Luscombe Share Registry Australian Legal Adviser Computershare Investor Services Pty Limited Yarra Falls, 452 Johnston Street Abbotsford VIC 3067 Becketts Lawyers Pty Ltd Level 34, 120 Collins Street Melbourne VIC 3000 Website: www.computershare.com/au SPP Offer website Auditor* www.computersharecas.com.au/ATXSPP2025 Grant Thornton Level 22, Tower 5 Collins Square, 727 Collins Street Melbourne VIC 3008 *The Auditor is included for information purposes only. It has not been involved in the preparation of this Prospectus and has not consented to being named in this Prospectus. Page |8 amtl0001_2500183_057.docx 2 CHAIRMAN’S LETTER Dear Shareholder On behalf of the Directors of Amplia, I am pleased to offer you the opportunity to apply for New Shares through participation in a share purchase plan. In conjunction with the SPP, the Company has completed the Unconditional Placement and is undertaking the Conditional Placement and Director Placement at the Placement Offer Price of $0.23 per New Share to raise a total of $25.0 million. Overview of Share Purchase Plan The SPP allows Eligible Shareholders the opportunity to subscribe for up to $100,000 worth of New Shares without paying brokerage or other transaction costs. The Company is seeking to raise up to $2.5 million under the SPP (which is subject to a scale-back policy), with the Company reserving the right to accept over-subscriptions of up to an additional $7.5 million worth of New Shares (up to a maximum of $10.0 million worth of New Shares). The SPP is being undertaken at the SPP Offer Price, which is the lower of: • the Placement Offer Price (of $0.23); and • the price representing a 5% discount to the volume weighted average price of Shares traded during the five trading days up to and including the Closing Date, rounded to the nearest half cent. The Placement Offer Price represents a discount of approximately 19.3% to the last closing price of Shares on 18 July 2025 (before the Capital Raising was announced). All the details pertaining to the SPP are contained in this Prospectus. Please read this Prospectus carefully. Use of proceeds of the Capital Raising The total funds raised from the Capital Raising (of up to approximately $27.5 million) are intended to be used by the Company to support the ACCENT and AMPLICITY trials, to initiate kRAS and OVARIAN trials of the Company’s lead drug, Narmafotinib (AMP 945), and to fund additional pre-clinical work and the costs of the Capital Raising. Further details are provided in Section 3.5. Action you should take Eligible Shareholders are entitled to subscribe to up to $100,000 worth of New Shares under the SPP. An Application Form will be available for Eligible Shareholders online at www.computersharecas.com.au/ATXSPP2025. An electronic copy of the Prospectus will accompany the Application Form. The SPP is scheduled to open on Friday, 1 August 2025 and close at 5.00pm (Melbourne time) on Friday, 22 August 2025. If you wish to subscribe for New Shares under the SPP, you must ensure that your Application and payment is received by this time in accordance with the instructions set out in Section 4.5. Prospectus This Prospectus contains important information regarding the SPP and I encourage you to read it carefully before making any investment decision, having particular regard to the ‘Risk Factors’ outlined in Section 7. Page |9 amtl0001_2500183_057.docx If you have any questions, you should consult your financial or other professional adviser. We look forward to your continued support of Amplia. Yours sincerely, Dr Warwick Tong Chairman Amplia Therapeutics Limited P a g e | 10 amtl0001_2500183_057.docx 3 OVERVIEW OF THE SPP AND SPP SHORTFALL OFFER 3.1 Overview of the Capital Raising On Wednesday, 23 July 2025, Amplia announced a Capital Raising to raise up to approximately $27.5 million (before costs), comprising the issue of New Shares in the following components. Unconditional Placement (a) An institutional placement at the Placement Offer Price to raise $22,265,000 (before costs), utilising the Company’s placement capacity under ASX Listing Rules 7.1 and 7.1A (Unconditional Placement). (b) The Unconditional Placement completed on 29 July 2025. Conditional Placement (c) An institutional placement at the Placement Offer Price to raise $2,500,000 (before costs), conditional on Shareholder approval for the purposes of ASX Listing Rule 7.1 (Conditional Placement). (d) Shareholders will vote on the Conditional Placement at the AGM (subject to applicable voting exclusions). Director Placement (e) (f) A placement to each of the Directors at the Placement Offer Price to raise a total of $235,000 as follows (the Director Placement): (i) 152,174 New Shares to Dr Warwick Tong (or nominee) to raise $35,000 (before costs); (ii) 130,435 New Shares to Ms Jane Bell (or nominee) to raise $30,000 (before costs); (iii) 86,957 New Shares to Dr Chris Burns (or nominee) to raise $20,000 (before costs); and (iv) 652,174 New Shares to Dr Robert Peach (or nominee) to raise $150,000 (before costs). The Director Placement is conditional on Shareholder approval for the purpose of Listing Rule 10.11. Shareholders will vote on the Director Placement at the AGM (subject to applicable voting exclusions). Share Purchase Plan (g) A share purchase plan (SPP or the Offer), under which Eligible Shareholders are entitled to apply for up to $100,000 worth of New Shares at the SPP Offer Price. (h) The Company is seeking to raise $2.5 million under the SPP, however, the Company reserves the right to accept over-subscriptions of up to an additional $7.5 million worth of New Shares under the SPP and SPP Shortfall Offer (for a total of $10.0 million). (i) The SPP Offer Price is the lower of: (i) the Placement Offer Price under the Placement, being $0.23; and P a g e | 11 amtl0001_2500183_057.docx (ii) the price representing a 5% discount to the volume weighted average price of Shares traded during the five trading days up to the Closing Date, rounded to the nearest half cent. (j) The Lead Manager has received firm commitments from certain Institutional Investors for up to $2.5 million worth of SPP Shortfall Shares under the SPP (in the event that the SPP receives Applications of less than $2.5 million). (k) The SPP is conditional on Shareholder approval for the purposes of ASX Listing Rule 7.1. Shareholders will vote on the SPP at the AGM (subject to applicable voting exclusions). (l) The SPP offer is being made under this Prospectus. (m) The Directors are not entitled to participate in the SPP (or the SPP Shortfall Offer). SPP Shortfall Offer 3.2 (n) The Company is seeking to raise $2.5 million under the SPP, however the Company reserves the right to accept over-subscriptions of up to an additional $7.5 million worth of New Shares under the SPP. Accordingly, the maximum amount to be raised under the SPP is $10.0 million of New Shares (the SPP Cap). (o) To the extent that New Shares up to the SPP Cap are not subscribed for under the SPP (SPP Shortfall Shares), the Company and the Lead Manager may seek to place the SPP Shortall Shares to Institutional Investors at the SPP Offer Price. (p) The SPP Shortfall Offer is conditional on Shareholder approval for the purposes of ASX Listing Rule 7.1. Shareholders will vote on the SPP Shortfall Offer at the AGM (subject to applicable voting exclusions). (q) The SPP Shortfall Offer is being made under this Prospectus. Eligible Shareholders Shareholders with a registered address in Australia or New Zealand who were registered in the Company’s Share register at the Record Date (7.00pm on Tuesday, 22 July 2025) are Eligible Shareholders and are entitled to participate in the SPP (other than in respect of Shares held on behalf of another person who is not an Eligible Shareholder). Due to foreign securities laws, it is not practical for Shareholders resident in countries other than Australia or New Zealand to be offered the opportunity to participate in the SPP (unless determined otherwise by the Directors at their discretion). 3.3 The SPP is being undertaken pursuant to this Prospectus In certain circumstances, a listed company may undertake a share purchase plan in accordance with ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 (Instrument 2019/547). Instrument 2019/547 allows a share purchase plan to be conducted without the use of a prospectus for a maximum of $30,000 worth of securities in a 12 month period. The Company is unable to rely on Instrument 2019/547 for the SPP because the SPP exceeds the monetary limit under Instrument 2019/547 as it is for up to $100,000 worth of New Shares to Eligible Shareholders. Accordingly, the Company is undertaking the SPP under this Prospectus. P a g e | 12 amtl0001_2500183_057.docx 3.4 The SPP and SPP Shortfall Offer are conditional on Shareholder approval The SPP and SPP Shortfall Offer are conditional on Shareholder approval for the purposes of ASX Listing Rule 7.1. This is because Amplia utilised substantially all of its capacity under ASX Listing Rules 7.1 and 7.1A under the Placement and is not entitled to rely on ASX Listing Rule 7.2, Exception 5 (which exempts securities issued under eligible share purchase plans from counting towards an entity’s capacity under ASX Listing Rule 7.1) because Eligible Shareholders are being offered up to $100,000 worth of New Shares under the SPP (meaning that it cannot rely on Instrument 2019/547). The resolution to approve the SPP and SPP Shortfall Offer will be considered at the AGM (to be held on Wednesday, 27 August 2025). If the SPP is not approved at the AGM it will not proceed. 3.5 Use of proceeds of the Capital Raising The Company intends to use the proceeds of the Capital Raising, together with its existing cash reserves (as disclosed in the Appendix 4C for the June 2025 quarter) and anticipated R&D Tax Rebates, as follows: Sources of funds Amount ($m) Use Amount ($m) Cash Balance* $7.0 ACCENT trial $6.0 Anticipated R&D Tax Rebates** Capital Raise proceeds^ Total $8.2 $27.5 $42.7 • Completion of Phase 2a • Foundational work for Phase 2b/3 trial Amplicity trial • Dose escalation • 2 Dose comparison $19.0 KRAS and/or OVARIAN trial $5.0 CMC (manufacturing) $6.0 Operations, preclinical, working capital and offer costs $6.7 Total $42.7 Notes: * Cash balance as at 30 June 2025. ** Subject to grant – Financial Year ending 2025 R&D tax refund expected August 2025 and Financial Year ending 2026 R&D tax refund expected August 2026. See ‘R&D Tax Rebate’ in Key Risks. ^ Assumes the SPP raises $2.5 million and the SPP, Conditional Placement and Director Placement are approved by Shareholders – see ‘Risks Associated with the Offer’ in Key Risks. The Board reserves the right to vary the uses of funds raised from the Capital Raising at its discretion and in the interests of Shareholders. To the extent that the SPP and SPP Shortfall Offer raises an amount exceeding $2.5 million, the additional funds will be used to progress Amplia’s trial program (ACCENT, AMPLICITY, kRAS and/or OVARIAN trials) and for CMC (manufacturing) purposes. P a g e | 13 amtl0001_2500183_057.docx 3.6 Scale-back policy The Company may, in its absolute discretion, undertake a scale-back of Applications under the SPP. In doing so, th